Senti Biosciences Inc (SNTI)

03:32 AM

Promising Biotech Stocks To Keep An Eye On – December 9th - Defense World

03:32 AM

Dec 11, 2025

Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Dec 11, 2025

Dec 11, 2025

Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial - geneonline.com

Dec 11, 2025

Dec 10, 2025

Senti Biosciences: Understanding the Market Moves - StocksToTrade

Dec 10, 2025

Dec 10, 2025

Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating - marketscreener.com

Dec 10, 2025

Dec 10, 2025

Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews

Dec 10, 2025

Dec 10, 2025

Senti Biosciences, Inc. (SNTI) Stock: Faces Decline Despite Groundbreaking FDA Designation - Mena FN

Dec 10, 2025

Dec 09, 2025

Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025) - ts2.tech

Dec 09, 2025

Dec 09, 2025

Unveiling Senti Biosciences: Shaping the Future of Cancer Therapy? - StocksToTrade

Dec 09, 2025

Dec 09, 2025

Senti Bio price target raised to $13 from $12 at Chardan - TipRanks

Dec 09, 2025

Dec 09, 2025

Why Is Gene Therapy Focused Senti Bio Stock Falling Today? - Benzinga

Dec 09, 2025

Dec 09, 2025

Lyft Stock Soars Following Strategic Euro Expansion Through FreeNow Acquisition - StocksToTrade

Dec 09, 2025

Dec 09, 2025

Senti Biosciences’ Strategic Moves Ripple Across Biotech Market - timothysykes.com

Dec 09, 2025

Dec 09, 2025

Senti Biosciences Secures FDA RMAT Designation For SENTI-202 - Nasdaq

Dec 09, 2025

Dec 09, 2025

Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up - Nasdaq

Dec 09, 2025

Dec 09, 2025

Senti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML - Nasdaq

Dec 09, 2025

Dec 09, 2025

Senti Biosciences’ Surge: Buy or Wait? - timothysykes.com

Dec 09, 2025

Dec 09, 2025

Senti Bio’s SENTI-202 shows promising results in AML clinical trial By Investing.com - Investing.com Canada

Dec 09, 2025

Dec 09, 2025

Senti Biosciences Reports Promising Phase 1 Trial Results - TipRanks

Dec 09, 2025

Dec 09, 2025

Senti Bio’s SENTI-202 shows promising results in AML clinical trial - Investing.com

Dec 09, 2025

Dec 09, 2025

Senti Bio stock soars after positive cancer therapy trial results By Investing.com - Investing.com Canada

Dec 09, 2025

Dec 09, 2025

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile - The Manila Times

Dec 09, 2025

Dec 09, 2025

Senti Biosciences, Inc. Announces Initial Clinical Data for SENTI-202 - TradingView

Dec 09, 2025

Dec 09, 2025

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia - marketscreener.com

Dec 09, 2025

Dec 09, 2025

Is Senti Biosciences Inc a good long term investmentLong-Term Investment Plans & Small Investment Growth Plans - earlytimes.in

Dec 09, 2025

Dec 04, 2025

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.

Dec 04, 2025

Dec 04, 2025

Senti Biosciences, Inc. to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented At the American Society of Hematology Annual Meeting 2025 - marketscreener.com

Dec 04, 2025

Dec 04, 2025

Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting - Quiver Quantitative

Dec 04, 2025

Dec 04, 2025

Senti Bio (Nasdaq: SNTI) to host Dec. 9 webcast on updated SENTI-202 data from ASH 2025 - Stock Titan

Dec 04, 2025

Dec 04, 2025

How Senti Biosciences Inc. stock reacts to oil pricesJuly 2025 Price Swings & Capital Efficiency Focused Strategies - Newser

Dec 04, 2025

Dec 02, 2025

Senti Biosciences (SNTI) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Nov 27, 2025

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - ADVFN

Nov 27, 2025

Nov 27, 2025

Form 8-KCurrent report - ADVFN

Nov 27, 2025

Nov 24, 2025

Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $8.75 Consensus PT from Analysts - Defense World

Nov 24, 2025

Nov 23, 2025

Leerink Partners Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World

Nov 23, 2025

Nov 22, 2025

SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN

Nov 22, 2025

Nov 22, 2025

Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating - Investing.com Australia

Nov 22, 2025

Nov 21, 2025

Leerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform Recommendation - Nasdaq

Nov 21, 2025

Nov 21, 2025

Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating By Investing.com - Investing.com South Africa

Nov 21, 2025

Nov 21, 2025

SNTI Stock Rating Update: Leerink Partners Initiates Coverage | - GuruFocus

Nov 21, 2025

Nov 20, 2025

Why Senti Biosciences Inc. stock is a must watch in 20252025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - newser.com

Nov 20, 2025

Nov 20, 2025

Is Senti Biosciences Inc. stock vulnerable to regulatory risksJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com

Nov 20, 2025

Nov 19, 2025

Why Senti Biosciences Inc. stock could benefit from AI revolutionWeekly Gains Summary & Technical Entry and Exit Tips - newser.com

Nov 19, 2025

Nov 19, 2025

Is Senti Biosciences Inc. trending in predictive chart modelsQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com

Nov 19, 2025

Nov 19, 2025

Combining machine learning predictions for Senti Biosciences Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com

Nov 19, 2025